Changes in the Characteristics of Patients Prescribed Selective Cyclooxygenase 2 Inhibitors After the 2004 Withdrawal of RofecoxibSETAKIS, E; LEUFKENS, H. G. M; VAN STAA, T. P et al.Arthritis care and research. 2008, Vol 59, Num 8, pp 1105-1111, issn 0893-7524, 7 p.Article

Use of nonsteroidal anti-inflammatory drugs and risk of fracturesVAN STAA, T. P; LEUFKENS, H. G. M; COOPER, C et al.Bone (New York, NY). 2000, Vol 27, Num 4, pp 563-568, issn 8756-3282Article

Utility of medical and drug history in fracture risk prediction among men and womenVAN STAA, T. P; LEUFKENS, H. G. M; COOPER, C et al.Bone (New York, NY). 2002, Vol 31, Num 4, pp 508-514, issn 8756-3282, 7 p.Article

Use of inhaled corticosteroids and risk of fracturesVAN STAA, T. P; LEUFKENS, H. G. M; COOPER, C et al.Journal of bone and mineral research (Print). 2001, Vol 16, Num 3, pp 581-588, issn 0884-0431Article

Venous thromboembolism among new users of different oral contraceptivesHERINGS, R. M. C; URQUHART, J; LEUFKENS, H. G. M et al.Lancet (British edition). 1999, Vol 354, Num 9173, pp 127-128, issn 0140-6736Article

From HMG through purified urinary FSH preparations to recombinant FSH: a substitution studyRIJKOM, J. E. F. Zwart-Van; BROEKMANS, F. J; LEUFKENS, H. G. M et al.Human reproduction (Oxford. Print). 2002, Vol 17, Num 4, pp 857-865, issn 0268-1161Article

Public health impact of adverse bone effects of oral corticosteroidsVAN STAA, T. P; ABENHAIM, L; COOPER, C et al.British journal of clinical pharmacology. 2001, Vol 51, Num 6, pp 601-607, issn 0306-5251Article

Epidemiology of fractures in England and WalesVAN STAA, T. P; DENNISON, E. M; LEUFKENS, H. G. M et al.Bone (New York, NY). 2001, Vol 29, Num 6, pp 517-522, issn 8756-3282Article

Between-country variation in the utilization of antihypertensive agents : guidelines and clinical practiceSTOLK, P; VAN WIJK, B. L. G; LEUFKENS, H. G. M et al.Journal of human hypertension. 2006, Vol 20, Num 12, pp 917-922, issn 0950-9240, 6 p.Article

Children and the risk of fractures caused by oral corticosteroidsVAN STAA, T. P; COOPER, C; LEUFKENS, H. G. M et al.Journal of bone and mineral research (Print). 2003, Vol 18, Num 5, pp 913-918, issn 0884-0431, 6 p.Article

Oral corticosteroids and fracture risk: relationship to daily and cumulative dosesVAN STAA, T. P; LEUFKENS, H. G. M; ABENHAIM, L et al.Rheumatology (Oxford. Print). 2000, Vol 39, Num 12, pp 1383-1389, issn 1462-0324Article

Predicting mortality in patients with heart failure: a pragmatic approachBOUVY, M. L; HEERDINK, E. R; LEUFKENS, H. G. M et al.Heart (London 1996). 2003, Vol 89, Num 6, pp 605-609, issn 1355-6037, 5 p.Article

Use of oral corticosteroids and risk of fractures. EditorialVAN STAA, T. P; LEUFKENS, H. G. M; ABENHAIM, L et al.Journal of bone and mineral research (Print). 2000, Vol 15, Num 6, pp 993-1005, issn 0884-0431Article

Incidence of antidepressant drug use in older adults and association with chronic diseases : The Rotterdam StudyEGBERTS, A. C. G; LEUFKENS, H. G. M; HOFMAN, A et al.International clinical psychopharmacology. 1997, Vol 12, Num 4, pp 217-223, issn 0268-1315Article

Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?VAN STAA, T.-P; RIETBROCK, S; SETAKIS, E et al.Journal of internal medicine. 2008, Vol 264, Num 5, pp 481-492, issn 0954-6820, 12 p.Article

5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease : a large epidemiological studyVAN STAA, T. P; CARD, T; LOGAN, R. F et al.Gut. 2005, Vol 54, Num 11, pp 1573-1578, issn 0017-5749, 6 p.Article

What is the harm-benefit ratio of Cox-2 inhibitors?VAN STAA, T. P; SMEETH, L; PERSSON, I et al.International journal of epidemiology. 2008, Vol 37, Num 2, pp 405-413, issn 0300-5771, 9 p.Article

Risk of fractures in patients with multiple sclerosis: A population-based cohort studyBAZELIER, M. T; STAA, T.-P. Van; UITDEHAAG, B. M. J et al.Neurology. 2012, Vol 78, Num 24, pp 1967-1973, issn 0028-3878, 7 p.Article

Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanerceptVAN LUIJN, J. C. F; DANZ, M; BIJISMA, J. W. J et al.Scandinavian journal of rheumatology. 2011, Vol 40, Num 3, pp 183-191, issn 0300-9742, 9 p.Article

Hospital discharge diagnoses of ventricular arrhythmias and cardiac arrest were useful for epidemiologic researchDE BRUIN, M. L; VAN HEMEL, N. M; LEUFKENS, H. G. M et al.Journal of clinical epidemiology. 2005, Vol 58, Num 12, pp 1325-1329, issn 0895-4356, 5 p.Article

Factors associated with switching from oral hypoglycaemic agents to insulin therapySPOELSTRA, J. A; STOLK, R. P; DE BRUYNE, M. C et al.Netherlands journal of medicine. 2002, Vol 60, Num 6, pp 243-248, issn 0300-2977Article

Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil usersSOUVEREIN, P. C; EGBERTS, A. C. G; MEULEMAN, E. J. H et al.International journal of impotence research. 2002, Vol 14, Num 4, pp 259-265, issn 0955-9930Article

Pyrazinamide use as a method of estimating under-reporting of tuberculosisVAN LOENHOUT-ROOYACKERS, J. H; LEUFKENS, H. G. M; HEKSTER, T. Y. A et al.International journal of tuberculosis and lung disease. 2001, Vol 5, Num 12, pp 1156-1160, issn 1027-3719Article

Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatmentEGBERTS, A. C. G; LENDERINK, A. W; DE KONING, F. H. P et al.Journal of clinical psychopharmacology. 1997, Vol 17, Num 3, pp 149-155, issn 0271-0749Article

Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implicationsABBING-KARAHAGOPIAN, V; HUERTA, C; HESSE, U et al.European journal of clinical pharmacology. 2014, Vol 70, Num 7, pp 849-857, issn 0031-6970, 9 p.Article